Page last updated: 2024-11-05

nitroethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nitroethane : A nitroalkane that is ethane substituted by a nitro group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID6587
CHEMBL ID15625
CHEBI ID16268
MeSH IDM0063442

Synonyms (52)

Synonym
NIE ,
CHEBI:16268 ,
1-nitroethane
nitroethan
c2h5no2
wln: wn2
nsc-8800
nsc8800
nitroetan
ethane, nitro-
inchi=1/c2h5no2/c1-2-3(4)5/h2h2,1h
NCGC00091797-01
un2842
einecs 201-188-9
hsdb 105
ccris 3088
nsc 8800
ai3-00110
nitroetan [polish]
C01837
nitroethane
79-24-3
CHEMBL15625
nitro-ethane
N0198
AKOS000120906
A839626
NCGC00091797-02
cas-79-24-3
dtxcid80969
dtxsid8020969 ,
NCGC00256603-01
tox21_302823
tox21_202217
NCGC00259766-01
ec 201-188-9
unii-6kel3zau0v
6kel3zau0v ,
nitroethane [un2842] [flammable liquid]
nitroethane [mi]
nitroethane [inci]
nitroethane [hsdb]
nitro ethane
nitroparaffin
un 2842
1-nitroethane #
nitroethane, reagentplus(r), 99.5%
nitroethane, reagent grade, >=98.0%
nitroethane, 97%
Q417316
nitroethane--d3
STL185643

Research Excerpts

Overview

Nitroethane is found to be a potent inhibitor of hydrogenotrophic methanogens in rumen fermentation process. It is a digestive inefficiency resulting in the loss of 2-15% of a ruminant's gross energy intake.

ExcerptReferenceRelevance
"Nitroethane is found to be a potent inhibitor of hydrogenotrophic methanogens in rumen fermentation process."( Pre-treatment of anodic inoculum with nitroethane to improve performance of a microbial fuel cell.
Ghangrekar, MM; Noori, MT; Rajesh, PP, 2018
)
1.47
"Nitroethane is a potent inhibitor of ruminal CH 4 production, a digestive inefficiency resulting in the loss of 2-15% of a ruminant's gross energy intake and an important emission source of this greenhouse gas. "( Effects of nitroethane and monensin on ruminal fluid fermentation characteristics and nitrocompound-metabolizing bacterial populations.
Anderson, RC; Cabrera-Diaz, E; Callaway, TR; Carstens, GE; Gutierrez-BaƱuelos, H; Krueger, NA; Nisbet, DJ; Pinchak, WE; Tedeschi, LO, 2008
)
2.18

Treatment

ExcerptReferenceRelevance
"Nitroethane treatment decreased (P<0.01) ruminal (8.46, 7.91 and 4.74+/-0.78 micromol/g/h) and fecal (3.90, 1.36 and 1.38+/-0.50 micromol/g/h) methane-producing activity for treatments 0X, 1X and 2X, respectively."( Zoonotic bacterial populations, gut fermentation characteristics and methane production in feedlot steers during oral nitroethane treatment and after the feeding of an experimental chlorate product.
Anderson, RC; Callaway, TR; Carstens, GE; Edrington, TS; Gutierrez-BaƱuelos, H; Horrocks, SM; Nisbet, DJ; Ramlachan, N; Slay, LJ, 2007
)
1.27

Dosage Studied

ExcerptRelevanceReference
" Throughout most of the investigation, body weights of both sexes of both exposed groups were slightly less than those of respective controls, but lack of a well-defined dose-response relationship suggested the involvement of factors other than just exposure to nitroethane."( Chronic inhalation exposure of rats to vapors of nitroethane.
Coulston, F; Griffin, TB; Stein, AA, 1988
)
0.71
" 1B is not appropriate, based on the fact that rat mammary and harderian tumors are likely not relevant to humans and lung and liver tumors reported in mice were equivocal in their dose-response and statistical significance."( Hazard characterization of carcinogenicity, mutagenicity, and reproductive toxicity for short chain primary nitroalkanes.
Garnick, L; Gillie, C; Kozal, J; Maier, A; Monnot, A; Quinn, J; Spencer, P, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary nitroalkaneA nitroalkane in which the nitro group is attached to a terminal carbon. Major microspecies at pH 7.3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
nitroethane degradation115

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency78.60530.001022.650876.6163AID1224839
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency41.33650.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.80260.000817.505159.3239AID1159531
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency70.05700.000627.21521,122.0200AID743202; AID743219
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID318681Anticarcinogenic activity in rat assessed as induction of tumors per day2008Bioorganic & medicinal chemistry, Mar-15, Volume: 16, Issue:6
QSAR modeling of the rodent carcinogenicity of nitrocompounds.
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (19.05)18.7374
1990's7 (11.11)18.2507
2000's29 (46.03)29.6817
2010's14 (22.22)24.3611
2020's1 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.52 (24.57)
Research Supply Index4.17 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index88.06 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (54.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (3.13%)6.00%
Case Studies3 (4.69%)4.05%
Observational0 (0.00%)0.25%
Other59 (92.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]